← Back to Clinical Trials
Recruiting NCT06570902

NCT06570902 Prospective WCD Post CABG Registry (CABG Registry)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06570902
Status Recruiting
Phase
Sponsor Zoll Medical Corporation
Condition Cardiomyopathy Ischemic
Study Type OBSERVATIONAL
Enrollment 910 participants
Start Date 2024-09-23
Primary Completion 2029-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
WCD

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 910 participants in total. It began in 2024-09-23 with a primary completion date of 2029-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective is to observe the rate of recovery of ventricular function (EF\>35%) after first-time coronary artery bypass graft surgery in patients who were prescribed the wearable cardioverter defibrillator (WCD) post-surgery prior to being discharged after hospitalization as part of standard clinical care.

Eligibility Criteria

Inclusion Criteria * Patient underwent first-time CABG surgery \<10 days before enrollment. * Patient is prescribed WCD for a primary reason of HF with reduced EF \< 35% measured after surgery but before hospital discharge. * Patient is ≥18 years old Exclusion Criteria: * Patients having combination CABG surgery with heart valve repair. * Patients with prior CABG. * Patients who have an active unipolar pacemaker. * Patients with a physical or mental condition that could impair their ability to properly interact with the WCD. Patients currently participating in an interventional clinical study. Patients with any skin condition that would prevent wearing the device. Patients with an advanced directive prohibiting resuscitation.

Contact & Investigator

Central Contact

Lars Weber, M.Sc.

✉ lweber@zoll.com

📞 015161140498

Frequently Asked Questions

Who can join the NCT06570902 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiomyopathy Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06570902 currently recruiting?

Yes, NCT06570902 is actively recruiting participants. Contact the research team at lweber@zoll.com for enrollment information.

Where is the NCT06570902 trial being conducted?

This trial is being conducted at Bad Nauheim, Germany, Hanover, Germany, Cottbus, Germany, Halle, Germany.

Who is sponsoring the NCT06570902 clinical trial?

NCT06570902 is sponsored by Zoll Medical Corporation. The trial plans to enroll 910 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology